J&J Covid-19 vaccine lasts at least 8 months, protects against Delta variant, studies find

J&J Vaccine gets emergency FDA approval

The Johnson & Johnson coronavirus vaccine provides immunity that lasts at least eight months, and it appears to provide adequate protection against the worrying Delta variant, the company said in a statement Thursday night.

"Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time," Dr. Mathai Mammen, head of research and development at J&J's Janssen vaccine arm, said in a statement.
The company said one dose of the vaccine elicits both a lasting antibody response and generates immune cells called T-cells that last eight months, also.

Dr. Dan Barouch of Beth Israel Deaconess Medical Center and Harvard Medical School and colleagues tested blood taken from 20 volunteers in an early stage, Phase 1/2 trial of the vaccine.
"These data are promising and reassuring," Barouch told CNN. Barouch has submitted his findings to the BioRxiv preprint server.
"Data showed that T-cell responses -- including CD8+ T-cells that seek out and destroy infected cells -- persisted over the eight-month timeframe examined," the company said.
These are not real-world efficacy data, but antibody and T-cell responses usually indicate protection, Barouch said.

Pfizer/BioNTech and Moderna have both said their two-dose vaccines are protective for at least six months and researchers at Washington University in St. Louis reported earlier this week that their studies of vaccinated volunteers indicate protection from the vaccines should last much longer than that-- even for years. They did not test the J&J vaccine.

Barouch's team also tested blood from the vaccinated volunteers against the most worrying variants of the virus, including the Delta or B.1.617.2 variant first seen in India, the B.1.351 or Beta variant first seen in South Africa, and the P.1 or Gamma variant spreading in Brazil.

"We see robust neutralizing antibody coverage of the variant," Barouch said. Neutralizing antibodies are the immune system proteins that inactivate a virus before it can replicate.

"A single dose of the Johnson & Johnson COVID-19 vaccine generated neutralizing antibodies against a range of SARS-CoV-2 variants of concern, which increased over time, including against the increasingly prevalent and more transmissible Delta (B.1.617.2) variant, the partially neutralization-resistant Beta (B.1.351), the Gamma (P.1) variants and others, including the Alpha (B.1.1.7), Epsilon (B.1.429), Kappa (B.1.617.1) and D614G variants, as well as the original SARS-CoV-2 strain," the company said.

Separately, a Janssen team in the Netherlands studied blood taken from eight vaccinated volunteers in the company's Phase 3 trial and found similar results against the variants.

Earlier Thursday, J&J said a second or booster dose of its vaccine would not be necessary.

Dr. Anthony Fauci agreed. "With regard to the idea of boosting, there's a lot of talk about that -- but right now I think we still need to remember that in fact, the J&J vaccine is a highly effective vaccine that has been recommended very clearly and has received an emergency use authorization," Fauci, who is director of the National Institute of Allergy and Infectious Diseases, told a White House briefing Thursday.

However, J&J, along with the US National Institutes of Health, is testing to see whether giving people two doses of its vaccine will provide better protection.

Story Courtesy

https://edition.cnn.com/2021/07/01/health/johnson-vaccine-delta-variant/index.html

Tags : #JohnsonJohnson #DeltaVariant #Covid19Vaccine #smitakumar #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Medanta organizes ‘Catwalk for Cancer’ to honour survivors’ strength and resilienceFebruary 10, 2025
Defence Minister, Shri. Rajnath Singh applauds the work done by Aero A2Z for manifesting ‘Make in India’ radar systems February 10, 2025
6 Things Every Young Woman Should Know About Reproductive HealthFebruary 10, 2025
Special Story on Epilepsy DayFebruary 10, 2025
Right wing policies threaten gender equality and health securityFebruary 10, 2025
Lumpy Skin Disease Wiped Out 200,000 Cattle: Can This New Vaccine Be The Ultimate Solution?February 10, 2025
The Future of Healthcare: A Self-Powered Sensor That Tracks Wound Healing Like Never BeforeFebruary 10, 2025
Deworming in Children: A Crucial Step Towards Healthy GrowthFebruary 07, 2025
AI-powered blue-collar hiring platform Vahan.ai secures investment from APAC HR services leader Persol Group amid booming gig economy in India; plans to develop AI recruitment technology to support 8 major Indian languages February 07, 2025
Scars That Never Heal: The Painful Reality of Female Genital MutilationFebruary 06, 2025
Maharashtra’s Healthcare Betrayal: Why Are Crucial Funds Going Unused?February 06, 2025
1vision, 1 mission: Avaada Foundation’s CSR initiatives are powering communities and delivering sustainable progress across 5 key focus areasFebruary 06, 2025
Top 5 Technology Brands that are Transforming the Cancer Care Journeys for Hospitals and PatientsFebruary 06, 2025
Women's Wellness brand NUA Raises Rs 35 Crore in Pre-Series C led by Mirabilis Investment TrustFebruary 06, 2025
8 Effective Ways to Minimize Postpartum ComplicationsFebruary 06, 2025
Does Where You Live Decide Your Fate? The Urban-Rural Breast Cancer Divide in IndiaFebruary 06, 2025
Nepal leads the world with largest pictorial health warnings on all tobacco productsFebruary 05, 2025
Fleetguard Filters Private Limited Recognized for Excellence in CSR at Navabharat’s 4th CSR ConclaveFebruary 05, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025